Riverwater Partners Sustainable Value Strategy highlighted stocks like Exelixis, Inc. (NASDAQ:EXEL), in the fourth quarter 2024 investor letter. Exelixis, Inc. (NASDAQ:EXEL) is an oncology company ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Scilex Holding Company (SCLX – Research Report) and Exelixis (EXEL – Research Report ...

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U ...

Exelixis (EXEL), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. When looking at the last two reports, this drug developer has ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of $42.00. The company’s shares closed ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology ...

After hours: 7:30:02 pm GMT-5 ...